CONCERT PHARMACEUTICALS: Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Read More »